Select a medication above to begin.
Yesafili (aflibercept-jbvf)
aflibercept intravitreal
Adult Dosing .
Dosage forms: INJ (vial): 2 mg per 0.05 mL
New FDA Approval: May 2024
- [content coming soon]
age-related macular degeneration, neovascular
- [content coming soon]
- Info: binds and inhibits vascular endothelial growth factor A and placental growth factor, decreasing neovascularization and vascular permeability
macular edema, retinal vein occlusion-associated
- [content coming soon]
- Info: binds and inhibits vascular endothelial growth factor A and placental growth factor, decreasing neovascularization and vascular permeability
diabetic macular edema
- [content coming soon]
- Info: binds and inhibits vascular endothelial growth factor A and placental growth factor, decreasing neovascularization and vascular permeability
diabetic retinopathy
- [content coming soon]
- Info: binds and inhibits vascular endothelial growth factor A and placental growth factor, decreasing neovascularization and vascular permeability
Peds Dosing .
- Dosage forms: --
New FDA Approval: May 2024
- [Peds dosing is not applicable for this drug]